CN104619839A - 药物递送蛋白质的增强运输的突变体的分离 - Google Patents

药物递送蛋白质的增强运输的突变体的分离 Download PDF

Info

Publication number
CN104619839A
CN104619839A CN201380041215.1A CN201380041215A CN104619839A CN 104619839 A CN104619839 A CN 104619839A CN 201380041215 A CN201380041215 A CN 201380041215A CN 104619839 A CN104619839 A CN 104619839A
Authority
CN
China
Prior art keywords
phage
seq
vector
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380041215.1A
Other languages
English (en)
Chinese (zh)
Inventor
拉里·K·梅迪纳-考维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CN104619839A publication Critical patent/CN104619839A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Ecology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380041215.1A 2012-08-03 2013-08-02 药物递送蛋白质的增强运输的突变体的分离 Pending CN104619839A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679306P 2012-08-03 2012-08-03
US61/679,306 2012-08-03
PCT/US2013/053493 WO2014022811A1 (en) 2012-08-03 2013-08-02 Isolating traffic-enhancing mutants of drug delivery protein

Publications (1)

Publication Number Publication Date
CN104619839A true CN104619839A (zh) 2015-05-13

Family

ID=50028570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041215.1A Pending CN104619839A (zh) 2012-08-03 2013-08-02 药物递送蛋白质的增强运输的突变体的分离

Country Status (18)

Country Link
US (2) US10036009B2 (https=)
EP (1) EP2880160B1 (https=)
JP (2) JP6618360B2 (https=)
KR (1) KR102115630B1 (https=)
CN (1) CN104619839A (https=)
AU (2) AU2013296218B2 (https=)
BR (1) BR112015002004A2 (https=)
CA (1) CA2881582A1 (https=)
DK (1) DK2880160T3 (https=)
ES (1) ES2703052T3 (https=)
IL (1) IL236955A0 (https=)
IN (1) IN2015DN01196A (https=)
MX (1) MX366347B (https=)
PL (1) PL2880160T3 (https=)
PT (1) PT2880160T (https=)
RU (1) RU2015105052A (https=)
WO (1) WO2014022811A1 (https=)
ZA (1) ZA201500739B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009441A2 (en) 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CA2881582A1 (en) * 2012-08-03 2014-02-06 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
DK2993983T3 (da) 2013-05-08 2020-05-18 Cedars Sinai Medical Center Målretningskorroler til tumortoksicitet og mri
EP3096773B1 (en) 2014-01-17 2020-07-01 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
US9850293B2 (en) 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002024934A1 (en) * 2000-09-22 2002-03-28 Consorzio Interuniversitario Per Le Biotecnologie Chimeric vectors and their use for heterologous genes transfer
EP1266963A1 (en) * 2001-06-15 2002-12-18 Crucell Holland B.V. Chimaeric phages
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439829A (en) 1991-01-30 1995-08-08 Eli Lilly And Company Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5547945A (en) 1993-07-15 1996-08-20 Jcr Pharmaceuticals Co., Ltd. Remitting agent for nephrotic syndrome and hepatopathy symptoms
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
JP3420586B2 (ja) * 1995-11-28 2003-06-23 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
WO1998035036A1 (en) * 1997-02-10 1998-08-13 Genentech, Inc. Heregulin variants
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
KR100609646B1 (ko) 1998-08-18 2006-08-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ｅｇｆ-ｒ 길항물질의 투여에 의한 기도 점액생산의 방지
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CA2415319A1 (en) 2000-06-16 2001-12-20 Martek Biosciences Corporation Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore
WO2002062823A2 (en) 2001-02-02 2002-08-15 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
US20060014712A1 (en) 2004-05-30 2006-01-19 Cemines, Inc. Controlled delivery of therapeutic compounds
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US20110052697A1 (en) 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
JP4479755B2 (ja) 2007-07-03 2010-06-09 ソニー株式会社 有機エレクトロルミネッセンス素子、及び、有機エレクトロルミネッセンス表示装置
MX2010005858A (es) * 2007-11-28 2010-06-11 Univ Pennsylvania Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CA2881582A1 (en) * 2012-08-03 2014-02-06 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
DK2993983T3 (da) 2013-05-08 2020-05-18 Cedars Sinai Medical Center Målretningskorroler til tumortoksicitet og mri
EP3096773B1 (en) 2014-01-17 2020-07-01 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
US9850293B2 (en) 2014-04-04 2017-12-26 Cedars-Sinai Medical Center Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
EA201892797A1 (ru) * 2016-05-27 2019-06-28 Седарс-Синаи Медикал Сентер Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002024934A1 (en) * 2000-09-22 2002-03-28 Consorzio Interuniversitario Per Le Biotecnologie Chimeric vectors and their use for heterologous genes transfer
EP1266963A1 (en) * 2001-06-15 2002-12-18 Crucell Holland B.V. Chimaeric phages
WO2009009441A2 (en) * 2007-07-06 2009-01-15 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells

Also Published As

Publication number Publication date
IL236955A0 (en) 2015-03-31
ES2703052T3 (es) 2019-03-06
PL2880160T3 (pl) 2019-03-29
MX366347B (es) 2019-07-05
US20150240231A1 (en) 2015-08-27
WO2014022811A1 (en) 2014-02-06
PT2880160T (pt) 2018-12-17
US20180298376A1 (en) 2018-10-18
AU2013296218A1 (en) 2015-02-19
US10036009B2 (en) 2018-07-31
JP2020002138A (ja) 2020-01-09
JP6618360B2 (ja) 2019-12-11
DK2880160T3 (en) 2019-01-14
ZA201500739B (en) 2018-07-25
RU2015105052A (ru) 2016-09-27
EP2880160B1 (en) 2018-09-19
IN2015DN01196A (https=) 2015-06-26
AU2013296218B2 (en) 2019-07-18
JP2015527343A (ja) 2015-09-17
KR102115630B1 (ko) 2020-05-27
EP2880160A4 (en) 2016-04-20
AU2019204815A1 (en) 2019-07-25
CA2881582A1 (en) 2014-02-06
MX2015001366A (es) 2015-08-13
BR112015002004A2 (pt) 2017-07-04
US10752893B2 (en) 2020-08-25
KR20150038543A (ko) 2015-04-08
EP2880160A1 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
US10752893B2 (en) Isolating traffic-enhancing mutants of drug delivery protein
Nicastro et al. Bacteriophage lambda display systems: developments and applications
JP6373301B2 (ja) バクテリオファージｔ４ ｄｎａパッケージングマシンを用いた遺伝子およびタンパク質のインビトロおよびインビボ送達
JP6956416B2 (ja) トランスポゾン系、それを含むキット及びそれらの使用
US20150010475A1 (en) Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
WO2017215619A1 (zh) 在细胞内产生点突变的融合蛋白、其制备及用途
AU2014267044A1 (en) Bacteriophage
CN109563489A (zh) 具有经修饰的糖蛋白d的疱疹病毒
CN109563490A (zh) 具有经修饰的糖蛋白b的疱疹病毒
CN110997914A (zh) 用于向细胞外囊泡装载化学和生物试剂/分子的组合物和方法
JP2007502129A (ja) 短鎖干渉ｒｎａライブラリーならびに合成および使用の方法
Liu et al. Systematic evolution of ligands by exosome enrichment: A proof‐of‐concept study for exosome‐based targeting peptide screening
JP2021502822A (ja) ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス
WO2024230738A1 (zh) 外囊泡融合蛋白及其应用
US20240301586A1 (en) A method for identifying peptide therapeutics to treat a variety of conditions
WO2026007591A1 (en) Checkpoint-blocking recombinant phage for cancer treatment
CN120441657A (zh) 一种靶向性重组载体及利用其制备car-m的方法
Ikwuagwu Systematic Engineering of Virus-Like Particles to Identify Self-Assembly Rules for Biotechnological Applications
WO2024243134A2 (en) Engineered bacteriophage particle and method of gene therapy by using same
Kritz Peptides from phage display libraries for targeted gene delivery via the p75NTR neurotrophic receptor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150513